Quantitative analysis for SpyGlass Pharma Inc. Common Stock (SGP) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (56.0) (grade B). 29 signals analyzed (25 differentiated alt-data).
SGP stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-05-05 | $25.00 | $23.75 | $24.41 |
| 2026-05-15 | $24.77 | $21.90 | $23.21 |
| 2026-05-28 | $20.57 | $19.45 | $19.84 |
| 2026-06-09 | $19.28 | $18.18 | $18.19 |
| 2026-06-22 | $19.73 | $18.43 | $19.34 |
| 2026-07-02 | $20.02 | $18.81 | $19.15 |
| 2026-07-15 | $21.34 | $19.65 | $20.60 |
| 2026-07-27 | $21.05 | $20.29 | $20.82 |
| 2026-08-06 | $24.99 | $23.74 | $24.75 |
| 2026-08-19 | $27.83 | $26.19 | $27.23 |
| 2026-08-31 | $26.64 | $25.62 | $26.10 |
| 2026-09-11 | $28.13 | $27.29 | $27.52 |
How SpyGlass Pharma Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
View all Health Care stocks by valuation and signals →
SpyGlass Pharma Inc. Common Stock (SGP) scores Buy (56.0), and the composite conceals a 77-point disagreement between its dimensions. It is strongest on competitive moat at 86 and technicals at 84, and weakest on analyst consensus at 9. A stock can carry competitive moat that high while analyst consensus sits at 9; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 86 |
| technicals | 84 |
| analyst consensus | 9 |
StoQuant analyzes 29 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on SpyGlass Pharma Inc. Common Stock (SGP): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/SGP"><img src="https://stoquant.com/badge/SGP.svg" alt="SpyGlass Pharma Inc. Common Stock (SGP) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.